Ocugen, Inc. — Director's Dealing 2015

Jun 26, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2015-06-24

Reporting Person: Baltzell Joshua J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-06-24	Stock Option (Right to Buy)	$6.86	A	20000	Acquired	2025-06-24	Common Stock (20000)	Direct

Footnotes

F1: This option vests in twelve (12) equal monthly installments commencing on the date of grant.